Processa Pharmaceuticals, Inc. Increase (Decrease) in Due from Related Parties
Processa Pharmaceuticals, Inc. (PCSA) reported Increase (Decrease) in Due from Related Parties of -$96.61 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueFromRelatedParties · last filed 2021-08-12
- Processa Pharmaceuticals, Inc. increase (decrease) in due from related parties for the quarter ending 2021-06-30 was $25.95K.
- Processa Pharmaceuticals, Inc. increase (decrease) in due from related parties for the quarter ending 2021-03-31 was -$122.56K, a 532.90% decline year-over-year.
- Processa Pharmaceuticals, Inc. increase (decrease) in due from related parties for the quarter ending 2020-12-31 was $188.06K, a 659.91% increase year-over-year.
- Processa Pharmaceuticals, Inc. increase (decrease) in due from related parties for the quarter ending 2020-09-30 was -$129.69K.
- Processa Pharmaceuticals, Inc. increase (decrease) in due from related parties for fiscal 2020 was $85.19K.
- Processa Pharmaceuticals, Inc. increase (decrease) in due from related parties for fiscal 2019 was -$21.90K, a 153.82% decline from fiscal 2018.
- Processa Pharmaceuticals, Inc. increase (decrease) in due from related parties for fiscal 2018 was $40.69K.
| Period end | Increase (Decrease) in Due from Related Parties 3 month | Increase (Decrease) in Due from Related Parties 6 month | Increase (Decrease) in Due from Related Parties 9 month | Increase (Decrease) in Due from Related Parties 12 month | Increase (Decrease) in Due from Related Parties 12 month as first filed |
|---|---|---|---|---|---|
| 2021-06-30 | $25.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$96.61K 10-Q · filed 2021-08-12 | $91.45K derived: sum of 3 quarters · filed 2021-08-12 | -$38.24K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2021-03-31 | -$122.56K 10-Q · filed 2021-05-13 | $65.50K derived: sum of 2 quarters · filed 2021-05-13 | -$64.19K derived: sum of 3 quarters · filed 2021-05-13 | -$65.69K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-12-31 | $188.06K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $58.38K derived: sum of 2 quarters · filed 2021-03-25 | $56.88K derived: sum of 3 quarters · filed 2021-08-12 | $85.19K 10-K · filed 2021-03-25 | |
| 2020-09-30 | -$129.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$131.19K derived: sum of 2 quarters · filed 2021-08-12 | -$102.88K 10-Q · filed 2020-11-12 | -$78.13K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-06-30 | -$1.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $26.81K 10-Q · filed 2021-08-12 | $51.56K derived: sum of 3 quarters · filed 2021-08-12 | $27.83K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $28.31K 10-Q · filed 2021-05-13 | $53.06K derived: sum of 2 quarters · filed 2021-05-13 | $29.33K derived: sum of 3 quarters · filed 2021-05-13 | -$19.17K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $24.75K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.02K derived: sum of 2 quarters · filed 2021-03-25 | -$47.48K derived: sum of 3 quarters · filed 2021-03-25 | -$21.90K 10-K · filed 2021-03-25 | $21.90K 10-K · filed 2020-03-06 |
| 2019-09-30 | -$23.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$72.23K derived: sum of 2 quarters · filed 2020-11-12 | -$46.65K 10-Q · filed 2020-11-12 | -$38.35K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$48.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$22.92K 10-Q · filed 2020-08-05 | -$14.62K derived: sum of 3 quarters · filed 2020-08-05 | $24.65K derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-03-31 | $25.58K 10-Q · filed 2020-05-15 | $33.88K derived: sum of 2 quarters · filed 2020-05-15 | $73.15K derived: sum of 3 quarters · filed 2020-05-15 | $102.30K derived: sum of 4 quarters · filed 2020-05-15 | |
| 2018-12-31 | $8.30K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $47.57K derived: sum of 2 quarters · filed 2020-03-06 | $76.72K derived: sum of 3 quarters · filed 2020-03-06 | $40.69K 10-K · filed 2020-03-06 | |
| 2018-09-30 | $39.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $68.42K derived: sum of 2 quarters · filed 2018-11-14 | $32.39K 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | $29.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$6.88K 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | -$36.02K 10-Q · filed 2018-05-21 | ||||
| 2017-09-30 | $27.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $35.23K derived: sum of 2 quarters · filed 2018-11-14 | $35.32K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $7.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $7.82K 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | $95.00 10-Q · filed 2018-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |